What is a stock summary page? Click here for an overview.
Current and historical daily PE Ratio for Vertex Pharmaceuticals Inc (
) from 1991 to Apr 25 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Vertex Pharmaceuticals stock (VRTX) PE ratio as of Apr 25 2025 is 0.
More Details
Vertex Pharmaceuticals Inc (VRTX) PE Ratio (TTM) Chart
Vertex Pharmaceuticals Inc (VRTX) PE Ratio (TTM) Historical Data
View and export this data going back to 1991. Start your Free Trial
Total 1213
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Vertex Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2025-04-25 | At Loss | 2025-02-20 | At Loss |
| 2025-04-24 | At Loss | 2025-02-19 | At Loss |
| 2025-04-23 | At Loss | 2025-02-18 | At Loss |
| 2025-04-22 | At Loss | 2025-02-14 | At Loss |
| 2025-04-21 | At Loss | 2025-02-13 | At Loss |
| 2025-04-17 | At Loss | 2025-02-12 | At Loss |
| 2025-04-16 | At Loss | 2025-02-11 | At Loss |
| 2025-04-15 | At Loss | 2025-02-10 | At Loss |
| 2025-04-14 | At Loss | 2025-02-07 | At Loss |
| 2025-04-11 | At Loss | 2025-02-06 | At Loss |
| 2025-04-10 | At Loss | 2025-02-05 | At Loss |
| 2025-04-09 | At Loss | 2025-02-04 | At Loss |
| 2025-04-08 | At Loss | 2025-02-03 | At Loss |
| 2025-04-07 | At Loss | 2025-01-31 | At Loss |
| 2025-04-04 | At Loss | 2025-01-30 | At Loss |
| 2025-04-03 | At Loss | 2025-01-29 | At Loss |
| 2025-04-02 | At Loss | 2025-01-28 | At Loss |
| 2025-04-01 | At Loss | 2025-01-27 | At Loss |
| 2025-03-31 | At Loss | 2025-01-24 | At Loss |
| 2025-03-28 | At Loss | 2025-01-23 | At Loss |
| 2025-03-27 | At Loss | 2025-01-22 | At Loss |
| 2025-03-26 | At Loss | 2025-01-21 | At Loss |
| 2025-03-25 | At Loss | 2025-01-17 | At Loss |
| 2025-03-24 | At Loss | 2025-01-16 | At Loss |
| 2025-03-21 | At Loss | 2025-01-15 | At Loss |
| 2025-03-20 | At Loss | 2025-01-14 | At Loss |
| 2025-03-19 | At Loss | 2025-01-13 | At Loss |
| 2025-03-18 | At Loss | 2025-01-10 | At Loss |
| 2025-03-17 | At Loss | 2025-01-08 | At Loss |
| 2025-03-14 | At Loss | 2025-01-07 | At Loss |
| 2025-03-13 | At Loss | 2025-01-06 | At Loss |
| 2025-03-12 | At Loss | 2025-01-03 | At Loss |
| 2025-03-11 | At Loss | 2025-01-02 | At Loss |
| 2025-03-10 | At Loss | 2024-12-31 | At Loss |
| 2025-03-07 | At Loss | 2024-12-30 | At Loss |
| 2025-03-06 | At Loss | 2024-12-27 | At Loss |
| 2025-03-05 | At Loss | 2024-12-26 | At Loss |
| 2025-03-04 | At Loss | 2024-12-24 | At Loss |
| 2025-03-03 | At Loss | 2024-12-23 | At Loss |
| 2025-02-28 | At Loss | 2024-12-20 | At Loss |
| 2025-02-27 | At Loss | 2024-12-19 | At Loss |
| 2025-02-26 | At Loss | 2024-12-18 | At Loss |
| 2025-02-25 | At Loss | 2024-12-17 | At Loss |
| 2025-02-24 | At Loss | 2024-12-16 | At Loss |
| 2025-02-21 | At Loss | 2024-12-13 | At Loss |
Vertex Pharmaceuticals Inc (VRTX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
VRTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
VRTX.USA0QZU.UKVRTX.MexicoVX1.GermanyVRTX34.BrazilVRTX.Austria1VRTX.Italy Index Membership
S&P 500NASDAQ 100Russell 1000Russell 3000 IPO Date
1991-07-31Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers